中草药

基于非靶向代谢组学探讨血脂康胶囊干预ApoE⁻/⁻小鼠冠状动脉微循环障碍的作用机制

PDF下载

中草药 | 药理与临床 2026,57(5): 1727-1741

收起

中草药 |药理与临床 2026 , 57 (5) : 1727 -1741

基于非靶向代谢组学探讨血脂康胶囊干预ApoE⁻/⁻小鼠冠状动脉微循环障碍的作用机制

全屏

张丽媛¹, 黄日康¹, 谭淇玲¹, 成璐¹, 张明倩¹, 程真真¹, 史浩男¹, 赵子阳¹, 张体¹, 刘曦², 裴欢², 樊利青², 贾占红¹, 张硕峰¹, 葛东宇³, 董世芬^1,4

作者信息

通讯作者:

葛东宇

作者简介:

张丽媛: 张丽媛,硕士研究生,研究方向为中药药理学。E-mail:13171269816@163.com

Mechanism of Xuezhikang Capsules on coronary microvascular dysfunction in ApoE^−/− mice based on untargeted metabolomics

ZHANG Liyuan, HUANG Rikang, TAN Qiling, CHENG Lu, ZHANG Mingqian, CHENG Zhenzhen, SHI Haonan, ZHAO Ziyang, ZHANG Ti, LIU Xi, PEI Huan, FAN Liqing, JIA Zhanhong, ZHANG Shuofeng, GE Dongyu, DONG Shifen

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.05.013

文章导航

摘要

收起

目的基于非靶向代谢组学探讨血脂康胶囊干预ApoE⁻/⁻小鼠冠状动脉微循环障碍（coronary microvascular dysfunction，CMD）的作用机制。方法 SPF级ApoE⁻/⁻小鼠高脂喂养7周后，尾iv月桂酸钠复制CMD模型，随机分为模型组、阿托伐他汀（6 mg/kg）组及血脂康低、中、高剂量（90、180、360 mg/kg）组，另取12只C57BL/6J小鼠作为对照组。给予药物干预8周后，采用苏木素-伊红（hematoxylin-eosin，HE）、Carstairs、Heidenhain染色检测小鼠心肌组织与心肌微血管形态与病理学变化；超声心动分析评估心脏功能性损伤；油红O染色评估主动脉脂质蓄积程度；生化法、ELISA法、免疫组化及免疫荧光检测血脂、心肌损伤及内皮功能相关指标；非靶向代谢组学技术分析小鼠粪便代谢物的变化，并分析差异代谢物与显著富集代谢通路；Western blotting检测心肌组织沉默信息调节因子1（silent information regulator 1，SIRT1）、过氧化物酶体增殖物激活受体γ共激活因子-1α（peroxisome proliferator activated receptor γ coactivator-1α，PGC-1α）、p-p65和p65蛋白表达。结果与模型组比较，血脂康胶囊可显著降低小鼠血清中三酰甘油、总胆固醇、低密度脂蛋白胆固醇水平以及心肌损伤和血管内皮损伤程度（P＜0.05、0.01），显著改善小鼠微血栓、心肌缺血和心功能下降程度（P＜0.01）。非靶向代谢组学鉴定出14种差异代谢物和15条富集通路（P＜0.05）。Western blotting结果显示，与模型组比较，血脂康胶囊可显著上调心肌组织SIRT1、PGC-1α的蛋白表达（P＜0.01），并下调p-p65/p65的蛋白表达（P＜0.01）。结论血脂康胶囊可发挥调血脂、改善内皮功能障碍和炎症反应作用，从而有效改善CMD模型小鼠心功能并减轻心肌结构损伤，其作用机制可能与调控精氨酸-脯氨酸-α-酮戊二酸代谢轴和eNOS/SIRT1/PGC-1α信号通路有关。

关键词

血脂康胶囊 / 冠状动脉微循环障碍 / ApoE^-/-小鼠 / 非靶向代谢组学 / 精氨酸-脯氨酸-α-酮戊二酸代谢轴 / eNOS/SIRT1/PGC-1α信号通路

Abstract

收起

Objective To investigate the mechanism of Xuezhikang Capsules (血脂康胶囊) in intervening coronary microvascular dysfunction (CMD) in ApoE^−/− mice based on non-targeted metabolomics. Methods After seven weeks of high-fat diet feeding, SPF-grade ApoE^−/− mice were injected with sodium laurate via tail vein to establish CMD model. The mice were then randomly divided into model group, atorvastatin (6 mg/kg) group, Xuezhikang low-, medium-, and high-dose (90, 180, 360 mg/kg) groups, another 12 C57BL/6J mice were selected as the control group. After eight weeks of drug intervention, the morphology and pathological changes of myocardial tissue and myocardial microvessels in mice were detected using hematoxylin-eosin (HE), Carstairs and Heidenhain staining. Cardiac functional injury was evaluated by echocardiography. Oil red O staining was used to evaluate the degree of lipid accumulation in the aorta. Lipid levels, myocardial injury and endothelial function-related indicators were detected by biochemical assays, ELISA, immunohistochemistry and immunofluorescence. The changes in fecal metabolites were analyzed using non-targeted metabolomics, and differential metabolites and significantly enriched metabolic pathways were identified. Western blotting was used to detect silent information regulator 1 (SIRT1), peroxisome proliferator activated receptor γ coactivator-1α (PGC-1α), p-p65 and p65 protein expressions in myocardial tissue. Results Compared with model group, Xuezhikang Capsules significantly reduced the levels of triglycerides, total cholesterol, low-density lipoprotein cholesterol, as well as the degree of myocardial and endothelial injury in serum of mice (P < 0.05, 0.01), and significantly improved the degree of microthrombus, myocardial ischemia and heart function decline in mice (P < 0.01). Non-targeted metabolomics identified 14 differentially expressed metabolites and 15 enriched pathways (P < 0.05). Western blotting results showed that compared with model group, Xuezhikang Capsules significantly up-regulated the protein expressions of SIRT1 and PGC-1α in myocardial tissue (P < 0.01), and down-regulated the protein expression of p-p65/p65 (P < 0.01). Conclusion Xuezhikang Capsules could regulate blood lipids, improve endothelial dysfunction and inflammatory response, thereby effectively improving cardiac function and reducing myocardial structural damage in CMD model mice. Its mechanism may be related to the regulation of arginine-proline-α-ketoglutarate metabolic axis and eNOS/SIRT1/PGC-1α signaling pathway.

Key words

Xuezhikang Capsules / coronary microvascular dysfunction / ApoE^-/- mice / untargeted metabolomics / arginine-proline-α-ketoglutarate metabolic axis / eNOS/SIRT1/PGC-1α signaling pathway

引用本文

张丽媛, 黄日康, 谭淇玲, 成璐, 张明倩, 程真真, 史浩男, 赵子阳, 张体, 刘曦, 裴欢, 樊利青, 贾占红, 张硕峰, 葛东宇, 董世芬. 基于非靶向代谢组学探讨血脂康胶囊干预ApoE⁻/⁻小鼠冠状动脉微循环障碍的作用机制. 中草药, 2026 , 57 (5) : 1727 -1741 . DOI: 10.7501/j.issn.0253-2670.2026.05.013

ZHANG Liyuan, HUANG Rikang, TAN Qiling, CHENG Lu, ZHANG Mingqian, CHENG Zhenzhen, SHI Haonan, ZHAO Ziyang, ZHANG Ti, LIU Xi, PEI Huan, FAN Liqing, JIA Zhanhong, ZHANG Shuofeng, GE Dongyu, DONG Shifen. Mechanism of Xuezhikang Capsules on coronary microvascular dysfunction in ApoE^−/− mice based on untargeted metabolomics[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (5) : 1727 -1741 . DOI: 10.7501/j.issn.0253-2670.2026.05.013

基金

收起

国家自然科学基金资助项目 (81503287); 北京市自然科学基金资助项目 (7232287)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Zhang W, Singh S, Liu L, et al. Prognostic value of coronary microvascular dysfunction assessed by coronary angiography-derived index of microcirculatory resistance in diabetic patients with chronic coronary syndrome[J]. Cardiovasc Diabetol, 2022, 21(1): 222.
Padro T, Manfrini O, Bugiardini R, et al. ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on ‘coronary microvascular dysfunction in cardiovascular disease’[J]. Cardiovasc Res, 2020, 116(4): 741-755.
Zhang W, Liu L, Chen H Y, et al. Association between the triglyceride-glucose index and the presence and prognosis of coronary microvascular dysfunction in patients with chronic coronary syndrome[J]. Cardiovasc Diabetol, 2023, 22(1): 113.
Fawaz S, Marin F, Khan S A, et al. Comparison of bolus versus continuous thermodilution derived indices of microvascular dysfunction in revascularized coronary syndromes[J]. Int J Cardiol Heart Vasc, 2024, 51: 101374.
Qiu Z J, Wang Y, Liu Y, et al. Diagnostic value of angiography-derived index of microcirculatory resistance (AMR) for coronary microcirculatory dysfunction (CMD) and its prognostic significance in patients with chronic coronary syndromes in the smoking population[J]. Medicine, 2024, 103(6): e37022.
Yang Z H, Liu Y X, Li Z Z, et al. Coronary microvascular dysfunction and cardiovascular disease: Pathogenesis, associations and treatment strategies[J]. Biomed Pharmacother, 2023, 164: 115011.
中国老年学和老年医学学会心脑血管病专业委员会, 血脂康胶囊临床应用中国专家共识组, 刘梅林, 等. 血脂康(胶囊)临床应用中国专家共识(2017修订版)[J]. 中华内科杂志, 2018, 57(2): 97-100.
乔宝进, 周政, 朱春胜, 等. 血脂康胶囊治疗小鼠代谢相关脂肪性肝病的作用机制及其对FXR通路相关蛋白的影响[J]. 现代药物与临床, 2025, 40(1): 30-36.
黄日康, 张丽媛, 臧子叶, 等. 血脂康通过PI3K/Akt/ eNOS通路防治冠状动脉微循环障碍疾病[J]. 中国现代中药, 2025, 27(2): 282-295.
Li W Z, Yang Y, Liu K, et al. FGL2 prothrombinase contributes to the early stage of coronary microvascular obstruction through a fibrin-dependent pathway[J]. Int J Cardiol, 2019, 274: 27-34.
庄园妃, 钟梅, 刘春贵, 等. 基于Nrf2/HO-1信号通路探讨冠心通络方对大鼠冠脉微循环障碍的影响[J]. 中药材, 2023, 46(4): 986-993.
Niewiara Ł, Kleczyński P, Guzik B, et al. Prevalence of coronary microcirculatory dysfunction in patients with chronic coronary syndromes and moderate coronary stenosis[J]. Kardiol Pol, 2025, 83(4): 465-473.
葛昭, 任秋安, 任思霖, 等. 理气化痰活血方对冠脉微循环障碍大鼠血管内皮功能及细胞凋亡的影响[J]. 世界中医药, 2025, 20(8): 1302-1312.
Zhao J X, Wang G D, Guan L N, et al. Establishment of nonobstructive coronary microcirculatory disorders in rabbits using three established methods and a comparative study[J]. Biochem Biophys Res Commun, 2024, 700: 149535.
Gabaldon-Perez A, Marcos-Garces V, Gavara J, et al. Coronary revascularization and long-term survivorship in chronic coronary syndrome[J]. J Clin Med, 2021, 10(4): 610.
夏迎龙, 姚璐, 田国祥, 等. 血小板及形态学参数与APOE基因多态性致动脉粥样硬化性血管疾病的分析[J]. 中国循证心血管医学杂志, 2025, 17(1): 78-82.
Liu H H, Zhao J J, Pan S L, et al. Shexiang Tongxin Dropping Pill protects against sodium laurate-induced coronary microcirculatory dysfunction in rats[J]. J Tradit Chin Med, 2021, 41(1): 89-97.
Veitch S, Njock M S, Chandy M, et al. miR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes[J]. Cardiovasc Diabetol, 2022, 21(1): 31.
Förstermann U, Xia N, Li H G. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis[J]. Circ Res, 2017, 120(4): 713-735.
Ford T J, Corcoran D, Padmanabhan S, et al. Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction[J]. Eur Heart J, 2020, 41(34): 3239-3252.
Lopez J J, Laham R J, Carrozza J P, et al. Hemodynamic effects of intracoronary VEGF delivery: Evidence of tachyphylaxis and NO dependence of response[J]. Am J Physiol, 1997, 273(3 Pt 2): H1317-H1323.
温小慧, 刘学红, 黄诗雅, 等. 加味芍药甘草汤对他莫昔芬诱导的子宫腺肌病小鼠血管生成相关因子的影响[J]. 中药新药与临床药理, 2025, 36(4): 515-521.
Shida T, Nozawa T, Sobajima M, et al. Fluvastatin-induced reduction of oxidative stress ameliorates diabetic cardiomyopathy in association with improving coronary microvasculature[J]. Heart Vessels, 2014, 29(4): 532-541.
Guo W, Zhang H P, Yang A N, et al. Homocysteine accelerates atherosclerosis by inhibiting scavenger receptor class B member1 via DNMT3b/SP1 pathway[J]. J Mol Cell Cardiol, 2020, 138: 34-48.
Koller A, Szenasi A, Dornyei G, et al. Coronary microvascular and cardiac dysfunction due to homocysteine pathometabolism a complex therapeutic design[J]. Curr Pharm Des, 2018, 24(25): 2911-2920.
Ambreen S, Fatima S, Elwakiel A, et al. Hypercoagulability impairs plaque stability in diabetes-induced atherosclerosis[J]. Nutrients, 2022, 14(10): 1991.
杨庆万, 周松, 陈春兰, 等. 基于代谢组学探索小檗碱对APC^min/+小鼠结直肠腺瘤的作用机制[J]. 中草药, 2024, 55(22): 7736-7745.
Rashid J, Kumar S S, Job K M, et al. Therapeutic potential of citrulline as an arginine supplement: A clinical pharmacology review[J]. Paediatr Drugs, 2020, 22(3): 279-293.
Ortiz-Vilchis P, Ortiz-Flores M, Pacheco M, et al. The cardioprotective effects of (−)-epicatechin are mediated through arginase activity inhibition in a murine model of ischemia/reperfusion[J]. Eur J Pharmacol, 2018, 818: 335-342.
曾钰, 闫磊, 刘亚林, 等. 外源脯氨酸对缺硼下棉花幼苗生长、生理特性以及脯氨酸代谢的影响[J]. 棉花学报, 2020, 32(3): 258-268.
Forlani G, Funck D. A specific and sensitive enzymatic assay for the quantitation of L-proline[J]. Front Plant Sci, 2020, 11: 582026.
Romani M, Hofer D C, Katsyuba E, et al. Niacin: An old lipid drug in a new NAD(⁺) dress[J]. J Lipid Res, 2019, 60(4): 741-746.
胡小露, 崔树梅, 柯崇榕, 等. 微生物合成L-脯氨酸和反式-4-羟基-L-脯氨酸的研究进展[J]. 生物工程学报, 2022, 38(12): 4498-4519.
Nikolaidou T, Mamas M, Oceandy D, et al. BAS/BSCR6α-ketoglutarate: Biological effects of a novel biomarker of heart failure[J]. Heart, 2010, 96(17): e14.1-e1e14.
Shi Y, Tian M, Zhao X F, et al. α-Ketoglutarate promotes cardiomyocyte proliferation and heart regeneration after myocardial infarction[J]. Nat Cardiovasc Res, 2024, 3(9): 1083-1097.
伍华燕, 温艺红, 赵亨利, 等. α-酮戊二酸介导异柠檬酸脱氢酶3A发挥抑制心肌细胞肥大的作用[J]. 中山大学学报: 医学科学版, 2025, 46(2): 275-283.
Hird F J R, Marginson M A. Formation of ammonia from glutamate by mitochondria[J]. Nature, 1964, 201(4925): 1224-1225.
Golatkar V, Bhatt L K. Artesunate attenuates isoprenaline induced cardiac hypertrophy in rats via SIRT1 inhibiting NF-κB activation[J]. Eur J Pharmacol, 2024, 977: 176709.

2026年第57卷第5期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.05.013

接收时间：2025-09-24
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-09-24

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.05.013

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT